LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
- PMID: 27999210
- PMCID: PMC5354729
- DOI: 10.18632/oncotarget.14002
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Abstract
Activating mutations in the KRAS and BRAF genes, leading to hyperactivation of the RAS/RAF/MAPK oncogenic signaling cascade, are common in patients with colorectal cancer (CRC). While selective BRAF inhibitors are efficacious in BRAFmut melanoma, they have limited efficacy in BRAFmut CRC patients. In a RASmut background, selective BRAF inhibitors are contraindicated due to paradoxical activation of the MAPK pathway through potentiation of CRAF kinase activity. A way to overcome such paradoxical activation is through concurrent inhibition of the kinase activity of both RAF isoforms. Here, we further examined the effects of LY3009120, a panRAF and RAF dimer inhibitor, in human models of CRC with various mutational backgrounds. We demonstrate that LY3009120 induced anti-proliferative effects in BRAFmut and KRASmut CRC cell lines through G1-cell cycle arrest. The anti-proliferative effects of LY3009120 in KRASmut CRC cell lines phenocopied molecular inhibition of RAF isoforms by simultaneous siRNA-mediated knockdown of ARAF, BRAF and CRAF. Additionally, LY3009120 displayed significant activity in in vivo BRAFmut and KRASmut CRC xenograft models. Examination of potential resistance to LY3009120 demonstrated RAF-independent ERK and AKT activation in the KRASmut CRC cell line HCT 116. These findings describe the preclinical activity of a panRAF inhibitor in a BRAFmut and KRASmut CRC setting.
Keywords: RAF; RAS; colorectal cancer; signaling pathways; xenograft models.
Conflict of interest statement
Authors affiliated with Eli Lilly and Company have Eli Lilly and Company shares received via 401(k) and bonus plans.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5354729/bin/oncotarget-08-9251-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5354729/bin/oncotarget-08-9251-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5354729/bin/oncotarget-08-9251-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5354729/bin/oncotarget-08-9251-g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5354729/bin/oncotarget-08-9251-g005.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5354729/bin/oncotarget-08-9251-g006.gif)
Similar articles
-
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23. Oncogene. 2018. PMID: 29059158
-
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.Cancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002. Epub 2015 Sep 3. Cancer Cell. 2015. PMID: 26343583
-
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30. Cancer Lett. 2017. PMID: 28576749
-
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Int J Mol Sci. 2015 Sep 23;16(9):22976-88. doi: 10.3390/ijms160922976. Int J Mol Sci. 2015. PMID: 26404261 Free PMC article. Review.
-
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.Pharmacol Res. 2018 Sep;135:239-258. doi: 10.1016/j.phrs.2018.08.013. Epub 2018 Aug 15. Pharmacol Res. 2018. PMID: 30118796 Review.
Cited by
-
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.NPJ Precis Oncol. 2024 May 31;8(1):124. doi: 10.1038/s41698-024-00615-9. NPJ Precis Oncol. 2024. PMID: 38822082 Free PMC article.
-
Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.Genes (Basel). 2024 Feb 3;15(2):202. doi: 10.3390/genes15020202. Genes (Basel). 2024. PMID: 38397192 Free PMC article.
-
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.Int J Mol Sci. 2024 Jan 28;25(3):1631. doi: 10.3390/ijms25031631. Int J Mol Sci. 2024. PMID: 38338909 Free PMC article. Review.
-
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Nat Rev Clin Oncol. 2024 Mar;21(3):224-247. doi: 10.1038/s41571-023-00852-0. Epub 2024 Jan 26. Nat Rev Clin Oncol. 2024. PMID: 38278874 Review.
-
DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis.Cancers (Basel). 2024 Jan 14;16(2):358. doi: 10.3390/cancers16020358. Cancers (Basel). 2024. PMID: 38254847 Free PMC article.
References
-
- Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931–7. doi: 10.1200/JCO.2009.22.4295. - DOI - PubMed
-
- Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. doi: 10.1038/nature11156. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous